Correlation of lower concentrations of hydrogen sulfide with atherosclerosis in chronic hemodialysis patients with diabetic nephropathy

Blood Purification

Volumn 38, Issue 3-4, 2014, Pages 188-194

  Li, Han ^a   Feng, Su Juan ^a   Zhang, Gui Zhi ^a   Wang, Shi Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hemodialysis; Hydrogen sulfide; TGF Smad signaling pathway; Uremic accelerated artherosclerosis

Indexed keywords

HYDROGEN SULFIDE; LOW DENSITY LIPOPROTEIN; MACROPHAGE ELASTASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY ECHOGRAPHY; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATIONAL STUDY; DIABETIC NEPHROPATHY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSDUCER; UREMIC ACCELERATED ATHEROSCLEROSIS; ADVERSE EFFECTS; BLOOD; CAROTID ARTERY DISEASES; COMMON CAROTID ARTERY; COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE COURSE; HYPERTENSION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; SMOKING; UREMIA; VASODILATATION; YOUNG ADULT;

ADULT; AGED; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROGEN SULFIDE; HYPERTENSION; MALE; MIDDLE AGED; RENAL DIALYSIS; SIGNAL TRANSDUCTION; SMAD PROTEINS; SMOKING; TRANSFORMING GROWTH FACTOR BETA1; UREMIA; VASODILATION; YOUNG ADULT;

EID: 84919967087     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000368883     Document Type: Article

References (50)

1. Sarnak MJ, Foley RN. Cardiovascular mortality in the general population versus dialysis: a glass half full or empty?. Am J Kidney Dis 2011; 58: 4-6.
2. Yadav AK, Banerjee D, Lal A, Jha V. Vitamin D deficiency, CD4+CD28null cells and accelerated atherosclerosis in chronic kidney disease. Nephrology (Carlton) 2012; 17: 575-581.
3. Inaba M, Maekawa K, Okuno S, Imanishi Y, Hayashino Y, Emoto M, Shoji T, Ishimura E, Yamakawa T, Nishizawa Y. Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 2012; 78: 273-280.
4. Koc Y, Unsal A, Kayabasi H, Oztekin E, Sakaci T, Ahbap E, Yilmaz M, Akgun AO. Impact of volume status on blood pressure and left ventricle structure in patients undergoing chronic hemodialysis. Ren Fail 2011; 33: 377-381.
5. Kaya Y, Ari E, Demir H, Soylemez N, Cebi A, Alp H, Bakan E, Gecit I, Asicioglu E, Beytur A. Accelerated atherosclerosis in haemodialysis patients; correlation of endothelial function with oxidative DNA damage. Nephrol Dial Transplant 2012; 27: 1164-1169.
6. Perna AF, Sepe I, Lanza D, Capasso R, Di Marino V, De Santo NG, Ingrosso D. The gasotransmitter hydrogen sulfide in hemodialysis patients. J Nephrol 2011; 23(suppl 16):S92-S96.
7. Perna AF, Luciano MG, Ingrosso D, Pulzella P, Sepe I, Lanza D, Violetti E, Capasso R, Lombardi C, De Santo NG. Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrol Dial Transplant 2009; 24: 3756-3763.
8. Li W, Tang C, Jin H, Du J. Effects of onion extract on endogenous vascular H2S and adrenomedulin in rat atherosclerosis. Curr Pharm Biotechnol 2011; 12: 1427-1439.
9. Du JT, Li W, Yang JY, Tang CS, Li Q, Jin HF. Hydrogen sulfide is endogenously generated in rat skeletal muscle and exerts a protective effect against oxidative stress. Chin Med J (Engl) 2013; 126: 930-936.
10. Jackson-Weaver O, Osmond JM, Riddle MA, Naik JS, Gonzalez Bosc LV, Walker BR, Kanagy NL. Hydrogen sulfide dilates rat mesenteric arteries by activating endothelial large-conductance Ca 2+-Activated K + channels and smooth muscle Ca2+ sparks. Am J Physiol Heart Circ Physiol 2013; 304:H1446-H1454.
11. van den Munckhof I, Scholten R, Cable NT, Hopman MT, Green DJ, Thijssen DH. Impact of age and sex on carotid and peripheral arterial wall thickness in humans. Acta Physiol (Oxf) 2012; 206: 220-228.
12. Bosevski M. Carotid IMT in type 2 diabetic patients: a survey on factors of influence. Prilozi 2011; 32: 289-297.
13. Tahir MA, Dmitrieva O, de Lusignan S, van Vlymen J, Chan T, Golmohamad R, Harris K, Tomson C, Thomas N, Gallagher H. Confidence and quality in managing CKD compared with other cardiovascular diseases and diabetes mellitus: a linked study of questionnaire and routine primary care data. BMC Fam Pract 2011; 12: 83.
14. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 2010; 78: 726-736.
15. Mejia-Rodriguez O, Herrera-Abarca JE, Ceballos-Reyes G, Avila-Diaz M, Prado-Uribe C, Belio-Caro F, Salinas-Gonzalez A, Vega-Gomez H, Alvarez-Aguilar C, Lindholm B, Garcia-Lopez E, Paniagua R. Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. Biomed Res Int 2013; 2013: 104059.
16. Ohsawa M, Tanno K, Itai K, Turin TC, Okamura T, Ogawa A, Ogasawara K, Fujioka T, Onoda T, Yoshida Y, Omama S, Ishibashi Y, Nakamura M, Makita S, Tanaka F, Kuribayashi T, Koyama T, Sakata K, Okayama A. Comparison of predictability of future cardiovascular events between chronic kidney disease (CKD) stage based on CKD epidemiology collaboration equation and that based on modification of diet in renal disease equation in the Japanese general population-Iwate KENCO study. Circ J 2013; 77: 1315-1325.
17. Marinelli A, Orlandi L, Stivali G. C-reactive protein levels are associated with arterial media calcification in nondiabetic patients with end-stage renal disease on long-Term hemodialysis. Clin Nephrol 2011; 76: 425-434.
18. Strozecki P, Donderski R, Kardymowicz A, Manitius J. Comparison of arterial stiffness in end-stage renal disease patients treated with peritoneal dialysis or hemodialysis. Pol Arch Med Wewn 2012; 122: 33-39.
19. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
20. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538.
21. Smink PA, Lambers Heerspink HJ, Gansevoort RT, de Jong PE, Hillege HL, Bakker SJ, de Zeeuw D. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis 2012; 60: 804-811.
22. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2011;59:A7, e1-e420.
23. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
24. Shibuya N, Kimura H. Production of hydrogen sulfide from d-cysteine and its therapeutic potential. Front Endocrinol (Lausanne) 2013; 4: 87.
25. Lavu M, Bhushan S, Lefer DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci (Lond) 2010; 120: 219-229.
26. Rivers JR, Badiei A, Bhatia M. Hydrogen sulfide as a therapeutic target for inflammation. Expert Opin Ther Targets 2012; 16: 439-449.
27. Francescato HD, Chierice JR, Marin EC, Cunha FQ, Costa RS, Silva CG, Coimbra TM. Effect of endogenous hydrogen sulfide inhibition on structural and functional renal disturbances induced by gentamicin. Braz J Med Biol Res 2012; 45: 244-249.
28. Hu LF, Lu M, Hon Wong PT, Bian JS. Hydrogen sulfide: neurophysiology and neuropathology. Antioxid Redox Signal 2011; 15: 405-419.
29. Gong QH, Shi XR, Hong ZY, Pan LL, Liu XH, Zhu YZ. A new hope for neurodegeneration: possible role of hydrogen sulfide. J Alzheimers Dis 2011; 24(suppl 2):173-182.
30. Desai KM, Chang T, Untereiner A, Wu L. Hydrogen sulfide and the metabolic syndrome. Expert Rev Clin Pharmacol 2011; 4: 63-73.
31. Liu F, Chen DD, Sun X, Xie HH, Yuan H, Jia W, Chen AF. Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiopoietin-1 in type 2 diabetes. Diabetes 2014;63: 1763-1778.
32. Ahmad FU, Sattar MA, Rathore HA, Abdullah MH, Tan S, Abdullah NA, Johns EJ. Exogenous hydrogen sulfide (H2S) reduces blood pressure and prevents the progression of diabetic nephropathy in spontaneously hypertensive rats. Ren Fail 2012; 34: 203-210.
33. Mikami Y, Shibuya N, Kimura Y, Nagahara N, Yamada M, Kimura H. Hydrogen sulfide protects the retina from light-induced degeneration by the modulation of Ca2+ influx. J Biol Chem 2011; 286: 39379-39386.
34. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 2010; 12: 1-13.
35. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, Lefer DJ. Hydrogen sulfide attenuates myocardial ischemiareperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 2007; 104: 15560-15565.
36. Snijder PM, de Boer RA, Bos EM, van den Born JC, Ruifrok WP, Vreeswijk-Baudoin I, van Dijk MC, Hillebrands JL, Leuvenink HG, van Goor H. Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolism. PLoS One 2013;8:e63291.
37. Bos EM, Leuvenink HG, Snijder PM, Kloosterhuis NJ, Hillebrands JL, Leemans JC, Florquin S, van Goor H. Hydrogen sulfideinduced hypometabolism prevents renal ischemia/ reperfusion injury. J Am Soc Nephrol 2009; 20: 1901-1905.
38. Liu H, Bai XB, Shi S, Cao YX. Hydrogen sulfide protects from intestinal ischaemia-reperfusion injury in rats. J Pharm Pharmacol 2009; 61: 207-212.
39. Fu Z, Liu X, Geng B, Fang L, Tang C. Hydrogen sulfide protects rat lung from ischemiareperfusion injury. Life Sci 2008; 82: 1196-1202.
40. Jha S, Calvert JW, Duranski MR, Ramachandran A, Lefer DJ. Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. Am J Physiol Heart Circ Physiol 2008; 295:H801-H806.
41. Lefer DJ. A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci U S A 2007; 104: 17907-17908.
42. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol 2004; 287:H2316-H2323.
43. Jiang HL, Wu HC, Li ZL, Geng B, Tang CS. Changes of the new gaseous transmitter H2S in patients with coronary heart disease. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 951-954.
44. Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, Tang X, Ren Y, Tang C, Du J. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2009; 29: 173-179.
45. Toma I, McCaffrey TA. Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res 2012; 347: 155-175.
46. Ohyama Y, Tanaka T, Shimizu T, Matsui H, Sato H, Koitabashi N, Doi H, Iso T, Arai M, Kurabayashi M. Runx2/Smad3 complex negatively regulates TGF-β-induced connective tissue growth factor gene expression in vascular smooth muscle cells. J Atheroscler Thromb 2011; 19: 23-35.
47. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadiere C, Renia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 2010;120: 422-432.
48. Belcaro G, Nicolaides AN, Laurora G, Cesarone MR, De Sanctis M, Incandela L, Barsotti A. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vasc Biol 1996; 16: 851-856.
49. Jadhav UM, Kadam NN. Apolipoproteins: correlation with carotid intimamedia thickness and coronary artery disease. J Assoc Physicians India 2004; 52: 370-375.
50. Mateo I, Morillas P, Quiles J, Castillo J, Andrade H, Roldan J, Agudo P, Bertomeu-Martinez V. What measure of carotid wall thickening is the best atherosclerotic loading score in the hypertensive patient: maximum or mean value?. Rev Esp Cardiol 2011; 64: 417-420.